Updates

The dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

The 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

Researchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

The study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.

New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.

The first-ever preventative treatment for migraine in adults, Aimovig (erenumab-aooe) is now approved by the Food and Drug Administration.

Lucemyra (lofexidine hydrochloride), now approved by the Food and Drug Administration, may offer relief (and new hope) for patients experiencing withdrawal symptoms from opioid dependence.

"We currently test for liver cancer using ultrasound and a blood protein marker called alpha fetoprotein," says John Kisiel, M.D., a gastroenterologist at Mayo Clinic. "Unfortunately, these tests are not very sensitive for curable stage liver cancers, and most patients who need this testing do not have it easily available or [are] not able to receive it often enough to be effective." The new advance by the team opens the door to further development of a DNA test. 

A team of researchers from the Leibniz-Institute of Freshwater Ecology and Inland Fisheries (IGB) has succeeded in demonstrating experimentally (in a lab) that genetic diversity makes populations more resistant to disease.

 

Researchers have built an ingestible sensor equipped with genetically engineered bacteria that can diagnose bleeding in the stomach or other gastrointestinal problems. Ultra-low-power sensors carrying genetically engineered bacteria can detect gastric bleeding. 

 

The Entomological Society of America reports today that a new study from the CDC (Centre for Disease Control) in the USA shows that permethrin-treated clothing may stop ticks from biting. This will thus reduce transmission of diseases like Lyme disease. Lab tests showed germ-carrying ticks can't move properly after contact with treated garments, making them sluggish and likely interfering with their ability to bite. 



 

Service Announcement for price changes to 12 medicines. For 9 medicines we have negotiated lower prices for patients, 3 medicines have increases. 

 

A personalised vaccine which boosts a patient’s own immune system has nearly doubled the number of women surviving ovarian cancer by two years.

Following an earlier negative decision, NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.

CLL expert explains latest treatment developments in the field.

Expert emphasises healthy lifestyle in prostate cancer care.

Kymriah, the first FDA-approved CAR-T cell therapy, is showing promising results in treating children with acute lymphoblastic leukemia.

The UK institute NICE gives 3 nods in thyroid cancer: Cometriq (cabozantinib), Nexavar (sorafenib) and Lenvima (lenvatinib).

Price decreases for 38 medicines

In a recent trial, 80% of patients with (MRD)-positive acute lymphoblastic leukemia (ALL) who were treated with a drug called Blincyto (blinatumomab) achieved a complete response.

Scientists experimenting with an innovative treatment for cancer have now devised a targeted injection that has already successfully eliminated tumours in mice.

The first ever patient to be treated with a new type of CAR-T cell therapy in a novel clinical trial is now in remission.

Remember the hypospray from Star Trek? Maybe it's close to reality.

A new combination of medicines is showing positive results in ER/HER2-Positive breast cancer.

A list of medicines TheSocialMedwork will soon be making available.

New test detects ovarian and 7 other cancers using simple blood sample.

Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.